Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Short-term Investments (2021 - 2025)

Terns Pharmaceuticals filings provide 5 years of Short-term Investments readings, the most recent being $494.2 million for Q4 2025.

  • Quarterly Short-term Investments rose 151.23% to $494.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $494.2 million through Dec 2025, up 151.23% year-over-year, with the annual reading at $494.2 million for FY2025, 151.23% up from the prior year.
  • Short-term Investments hit $494.2 million in Q4 2025 for Terns Pharmaceuticals, up from $144.9 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $494.2 million in Q4 2025 and bottomed at $96.8 million in Q1 2021.
  • Average Short-term Investments over 5 years is $164.1 million, with a median of $136.8 million recorded in 2022.
  • The largest annual shift saw Short-term Investments tumbled 55.12% in 2024 before it surged 151.23% in 2025.
  • Terns Pharmaceuticals' Short-term Investments stood at $118.3 million in 2021, then increased by 18.26% to $139.9 million in 2022, then skyrocketed by 31.19% to $183.5 million in 2023, then grew by 7.2% to $196.7 million in 2024, then soared by 151.23% to $494.2 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Short-term Investments are $494.2 million (Q4 2025), $144.9 million (Q3 2025), and $169.5 million (Q2 2025).